Skip to content
Menu

Protara Therapeutics, Inc. TARA

Full chart Compare
Set alert

Price alert · TARA

All alert types
2.38 USD -0.15 (-5.93%)

Regular-session close

2.42 +0.04 +1.68%

After hours · Nov 16, 4:41 PM ET

2.36 Day range 2.52
2.09 52-week range 7.82
YTD
-55.35%
1 year
-56.81%
Market cap
146.54M
EPS (ttm)
-1.39
Shares out
34.32M
Forward P/E
-1.61
YTD return
-55.35%
1-year return
-56.81%
50-day average
3.22
200-day average
2.74
Enterprise value
-31.37M
Volume
631.32K
Avg volume
1.02M
Open
2.52
Previous close
2.53
Day's range
2.36 – 2.52
52-week range
2.09 – 7.82
Beta
1.79
Analysts
Strong Buy
Price target
26.40 (+1009.2%)

 

No chart data for this range yet.

Key statistics

Price / book
0.86
Free cash flow
-20.31M
Total cash
89.58M
Total debt
4.98M
Return on equity
-45.91%
Short % of float
17.65%

Fundamental scorecard

3 of 25 checks passed on TARA’s reported financials

ValueGrowthProfitabilityHealthDividend

3of 25 checks passed

  • Value 0 of 5
  • Growth 0 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
TARA Revenue — quarterly 0
TARA Net income — quarterly -21.69M
TARA EPS — quarterly -0.35

Earnings

TARA recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 12, 2024Sep 1, 2024-0.50-0.500.000.00%
Aug 6, 2024Jun 1, 2024-0.82-0.45+0.37+45.12%
May 2, 2024Mar 1, 2024-0.99-0.97+0.02+2.02%
Mar 13, 2024Dec 1, 2023-1.03-0.90+0.13+12.62%
Nov 3, 2023Sep 1, 2023-1.10-0.87+0.23+20.91%
Aug 3, 2023Jun 1, 2023-0.97-1.00-0.03-3.09%

Upgrades / downgrades

TARA analyst upgrades and downgrades
DateFirmActionFromTo
Dec 6, 2024GuggenheimreitBuyBuy
Dec 6, 2024HC Wainwright & Co.reitBuyBuy
Nov 14, 2024HC Wainwright & Co.reitBuyBuy
Aug 12, 2024OppenheimermainOutperformOutperform
Aug 8, 2024HC Wainwright & Co.reitBuyBuy
May 6, 2024HC Wainwright & Co.reitBuyBuy

About Protara Therapeutics, Inc.

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on TARA — it syncs with the Stock Master app.

Insider holders

TARA insider holders
InsiderRelationLatest transactionDateShares held
BANDARI JATHINOfficerStock Award(Grant)Jan 18, 202456,704
FABBIO PATRICKChief Financial OfficerStock Award(Grant)Jan 18, 202422,000
FRY HANNAHOfficerStock Award(Grant)Jan 18, 202429,836
OPALEYE MANAGEMENT, INC.Beneficial Owner of more than 10% of a Class of SecuritySaleSep 11, 20240
SHEFFERMAN JESSE MChief Executive OfficerStock GiftAug 27, 2024935,501
ZUMMO JACQUELINEOfficerStock Award(Grant)Jan 18, 2024104,296

Institution ownership

TARA institution ownership
Holder% heldSharesValueReported
RA Capital Management, L.P.9.21%1,900,0009.79MSep 29, 2024
Opaleye Management Inc.8.15%1,681,1548.66MSep 29, 2024
Stempoint Capital LP 4.57%942,8574.86MSep 29, 2024
Woodline Partners LP4.13%851,5674.39MSep 29, 2024
Boxer Capital, LLC3.93%811,6274.18MSep 29, 2024
Vanguard Group Inc3.68%759,6123.91MSep 29, 2024

Fund ownership

TARA fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund2.99%616,3013.17MSep 29, 2024
Vanguard Extended Market Index Fund0.68%140,668724.44KSep 29, 2024
Fidelity Extended Market Index Fund0.47%97,351501.36KOct 30, 2024
Bridgeway Funds Inc-Ultra Small Company Market Fund0.24%49,200253.38KSep 29, 2024
iShares Micro Cap ETF0.20%41,236212.37KOct 30, 2024
Fidelity Total Market Index Fund0.15%30,335156.22KOct 30, 2024